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Abstract
Purpose In children, data on the combined impact of age,
genotype, and disease severity on tacrolimus (TAC) disposition
are scarce. The aim of this study was to evaluate the effect of
these covariates on tacrolimus dose requirements in the
immediate post-transplant period in pediatric kidney and liver
recipients.
Methods Data were retrospectively collected describing tacro-
limus disposition, age, CYP3A5 and ABCB1 genotype, and
pediatric risk of mortality (PRISM) scores for up to 14 days
post-transplant in children receiving liver and renal trans-
plants. Initial TAC dosing was equal in all patients and
adjusted using therapeutic drug monitoring. We determined
the relationship between covariates and tacrolimus disposition.
Results Forty-eight kidney and 42 liver transplant recipients
(median ages 11.5 and 1.5 years, ranges 1.5–17.7 and 0.05–
14.8 years, respectively)received TAC post-transplant.In both
transplant groups, younger children (<5 years) needed higher
TAC doses than older children [kidney: 0.15 (0.07–0.35) vs.
0.09 (0.02–0.20) mg/kg/12h, p=0.046, liver: 0.12 (0.04–
0.32) vs. 0.09 (0.01–0.18) mg/kg/12h, p=0.038]. In kidney
but not liver transplants, CYP3A5 expressors needed
significantly higher TAC doses than nonexpressors [0.15
(0.07–0.20) vs. 0.09 (0.02–0.35) mg/kg/12h, P=0.001]. In
these patients, age and CYP3A5 genotype were indepen-
dently associated with TAC dosing requirement. In liver, but
not kidney transplant patients, homozygous ABCB1 T-T-T
haplotype carriers needed higher TAC doses than noncarriers
[0.26 (0.15–0.32) vs. 0.11 (0.01–0.25) mg/kg/12h, p=0.013].
Conclusion CYP3A5 genotype may explain variation in
tacrolimus disposition early after transplant in pediatric
kidney recipients, independent of age-related variation. In
contrast, in pediatric liver recipients, variation in tacrolimus
disposition appears related to age and ABCB1 genotype. These
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Introduction
Tacrolimus is a potent immunosuppressive drug, used in
most pediatric solid organ transplant recipients to prevent
transplant rejection. This drug is characterized by a narrow
therapeutic window and high inter- and intraindividual
variability in disposition [1]. Drug concentrations can show
up to 100-fold variation in individual patients. Transplant
rejection rates as well as most of the adverse events
associated with tacrolimus (including nephrotoxicity, neu-
rotoxicity, hypertension, infections, and lymphoproliferative
disease) may be, at least partially, concentration-related [2].
These serious adverse events associated with tacrolimus
therapy provide a compelling rationale for the use of
rigorous therapeutic drug monitoring. This is especially true
because, with a tacrolimus half-life of up to 40 h, it may
take 3–5 days before a tacrolimus dosing adjustment results
in a new, adequate blood concentration [2]. All this time the
patient may be at an increased risk for transplant rejection
or adverse events.
Tacrolimus pharmacokinetics has been extensively in-
vestigated in adults. However, data in children are more
limited [3]. Young children (1–6 years of age) appear to
need higher doses per kilogram body weight of tacrolimus
than older children and adults to maintain similar trough
concentrations. The reason for this age-related faster
clearance rate is unknown.
In addition to age-related differences in tacrolimus
pharmacokinetics, large inter- and intraindividual variation
is observed due to other factors. For example, genetic
variation in CYP3A5 has been shown to explain a large part
of the variation in tacrolimus disposition in both adult and
small cohorts of pediatric solid organ transplant patients, as
recently reviewed by Quteineh et al. [4–12]. The impact of
genetic variation in ABCB1 gene activity on tacrolimus
disposition remains controversial to date [13].
The impact of age and genetic variation appears to be
weakened in the immediate post-transplantation period, while
intraindividual variation appears larger [14]. This finding
may be explained by other factors affecting tacrolimus
disposition postoperatively. For example, CYP3A activity
appears to be downregulated by proinflammatory factors,
mainly TNFα, IL-1, and IL-6, which may be released after
organ transplant surgery [15]. Yet, data regarding the effect
of inflammation or disease severity on tacrolimus disposition
in the immediate post-transplant period are lacking.
While limited data on the effect of age and CYP3A5
genotype on tacrolimus pharmacokinetics in children
exist, the interplay of age, CYP3A5 genotype, and disease
severity in relation to tacrolimus pharmacokinetics in
pediatric solid transplant patients has not been elucidated,
especially not in the immediate post-transplant period,
when variation appears to be largest. This is important, as
age-related changes in pharmacokinetics may obscure
genetic variation. Similarly, inflammation and/or organ
failure may reduce drug metabolism in patients who
would otherwise have tacrolimus clearance comparable
to adults or even faster. Due to this lack of data on the
interplay of these possible covariates, the pediatric
transplant patient is subjected to a higher risk of adverse
events or transplant rejection.
The aim of this study was therefore to retrospectively
determine the combined effect of age, CYP3A5 and ABCB1
genotype, and disease severity on tacrolimus dosing
requirements and disposition in a cohort of pediatric liver
and kidney recipients in the 2 weeks following transplan-
tation. These two patient groups differ in that, in the liver
transplant patients, recipient CYP3A5 and ABCB1 genotype
may only affect intestinal CYP3A5 and ABCB1 activity,
whereas in the kidney transplant patients, CYP3A5/ABCB1
genotype may affect both intestinal and liver CYP3A5/
ABCB1 activity.
Methods and materials
Study design
Retrospective cohort study in pediatric liver and kidney
transplant patients who received tacrolimus in the first 14
days after transplant.
Patient population
Patients were eligible for study entry if they were 0–18
years of age at the time of liver or kidney transplant and
received tacrolimus during the first 14 days post-
transplant between 2000 and 2008 at the Hospital for
Sick Children, Toronto, Ontario. From December 2006 to
March 2008, all patients who visited the Outpatient
Transplant Clinic or who were admitted to the hospital
for transplant or follow-up were approached for informed
consent. Transferred patients (out of the SickKids
program) or deceased patients were not included. For
deceased patients no DNA was available. The study was
approved by the Hospital for Sick Children’s Research
Ethics Board. Informed consent and, if applicable, child-
ren’s assent were obtained from all parents/legal repre-
sentatives and/or patients.
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All patients were started by the transplant physician on
SickKid’s transplant immunosuppression protocol therapy
consisting of methylprednisolone, mycophenolate mofe-
til, and tacrolimus. A minority of patients received
basiliximab or thymoglobulin (Table 1). Methylpredniso-
lone (10 mg/kg) was intravenously administered at the
time of graft reperfusion and gradually tapered after
transplant (Table 1). Tacrolimus starting dose was 0.1
m g / k go r a l l yt w i c ed a i l yi na l lp a t i e n t sa n dw a ss u b s e -
q u e n t l ya d j u s t e db yr o u t i n epre-dose tacrolimus concen-
trations to reach the preset target tacrolimus C0
concentration of 10–15 ng/ml for both groups. No
predefined dose adaptation algorithm was used. Doses
were adapted by the transplant physician in collaboration
with the hospital pharmacist.
Clinical data collection
The following patient characteristics were collected from
SickKids electronic patient databases: transplant type,
age at transplant, sex, weight, PRISM III score, duration
of mechanical ventilation and ICU stay, chemical and
hematological test results, and relevant co-medication
(CYP3A5/ABCB1 inducers/inhibitors). Initial liver graft
failure was defined as ASAT and/or ALAT >1,500 IU/l in
the first 72 h after transplant, as defined by Nanashima
et al. [16].
The following information was collected on tacrolimus:
doses (date/time) and tacrolimus morning pre-dose blood
concentrations (date/time).
The PRISM III score is a widely used and validated
score in the pediatric intensive care setting assessing the
severity of illness and the potential risk of mortality in
critically ill children [17]. The PRISM is based on 14
routinely measured clinical and laboratory parameters with
age-normalized normal ranges [17].
Outcome measures
The primary outcome measure was median tacrolimus
dosing requirement (normalized for body weight). Second-
ary outcome measures were median tacrolimus concen-
trations and concentration/dose ratio (normalized for body
weight), as surrogate marker for tacrolimus clearance.
Independent variables
Independent variables included recipient age, CYP3A5
and ABCB1 genotype, and PRISM score.
DNA collection
For DNA analysis, blood for DNA (0.5 ml) was collected
during regular blood work at the Transplant Outpatient
Clinic. In cases where DNA collection from blood was not
possible, saliva was collected using the Oragene TM DNA
Table 1 Characteristics of the 90 pediatric liver and kidney transplant recipients
Kidney Liver P-value
Number Median Range Number Median Range
Male/female 29/19 0.39
Weight (kg) 48 33.7 10.7–80 42 10.9 2.6–64 <0.000
Age (years) 48 11.5 1.5–17.7 42 1.5 0.05–14.8 <0.000
PRISM 40 7 2–16 30 7.5 0–28 0.497
Days in ICU 48 2 1–14 42 6 2–14 <0.000
Days on ventilator 48 0–44 2 10 –12 <0.000
Mean airway pressure (cm H2O) 3 13 11–14 31 11 8–18 0.214
Urinary output (mL/kg/u) 42 5.0 1.5–30.4 42 3 0.8–5.9 <0.000
Creatinin (μmol/L) 48 87.0 19–415 42 26.3 14–138 0.000
Albumin (g/L) 48 31.3 26.7–37 42 31.0 20–37 0.255
Hematocrit (L/L) 48 0.3 0.23–0.48 42 0.3 0.25–0.45 0.017
Methylprednisolone dose
Day 1 (mg/kg/day) 48 2 0.7–3 42 3.9 1.8–4
Day 7 (mg/kg/day) 48 1.6 1.5–1.8 42 0.3 0.1–0.3
Day 14 (mg/kg/day) 48 1.2 1.0–1.5 42 0.28 0.05–0.3
Basiliximab (yes/no) 0/48 6/36
Thymoglobulin (yes/no) 2/46 4/38
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(DNA Genotek, Kanata, ON).
Laboratory analysis
Tacrolimus concentrations Tacrolimus blood concentrations
were determined in EDTAwhole blood (0.25 ml), using LC-
MS-MS as described previously [18].
Genotyping Genomic DNA was isolated from 0.2 ml ethyl-
enediaminetetraacetic acid-treated whole blood using a Magna-
Pure LC (Roche Diagnostics, Mannheim, Germany). Genotyp-
ing was done using Taqman allelic discrimination assays on the
API Prism 7900 HT sequence detection system (Applied
Biosystems, CA, USA) on 1 ng of genomic DNA, as previously
reported [19, 20]. Patients not carrying the CYP3A5*3 allele
were assigned the CYP3A5*1/*1 genotype by default. For the
allelic variant G2677A/T, two separate assays were designed,
one detecting G2677T, one detecting G2677A.
Statistical analyses
Data are presented as mean±SD or median (range) when
the data were not normally distributed.
CYP3A5 and ABCB1 genotypes were tested for Hardy-
Weinberg equilibrium. For the results, we compared mean
differences using t-test or the rank-sum test when the data
were not normally distributed. As the ABCB1 polymor-
phisms are expected to be in linkage disequilibrium,
multiple testing does not apply to the three different
genotypes and one haplotype [21]. For comparison of
categorical variables, chi-squared or Fisher’s exact test was
used, as appropriate. We studied correlations using Spear-
man’s correlation test. With an expected cohort of 100
patients to be included (50 liver, 50 kidney), we a priori
restricted our analysis to a maximum of four variables (age,
CYP3A5 and ABCB1 genotype, and PRISM score), based
on the general rule of thumb for multiple regression
analysis that 10–20 patients are needed per variable.
To test the relative contribution and interaction of
significant covariates from univariate analysis, multivariate
analysis was performed using a general linear model. Data
analysis was performed using SPPS statistical software
(SPSS 16.0, Chicago, IL)
Results
Patient inclusion and clinical characteristics
The total transplanted patient cohort at the Hospital for Sick
Children transplant unit as of February 2008 was 124
kidney and 91 liver transplant patients. Of these patients,
approximately 80% received tacrolimus in the first 2 weeks
of transplant. All patients who received tacrolimus in the
first 2 weeks after transplant were approached for informed
consent when they visited the SickKids Transplant Outpa-
tient clinic between November 2006 and February 2008. In
addition, all patients who received a new transplant during
this period were asked for informed consent. Informed
consent rate was >95%. Patients that were missed were
patients that moved out of the Toronto area or that were
transferred to the adult transplant clinic for follow-up. In
addition, patients that passed away could not be included,
as we could not obtain DNA from these patients.
Between December 2006 and March 2008, 42 pediatric
liver recipients and 48 kidney recipients were enrolled
(Table 1). The liver recipients were much younger than the
kidney recipients [median (range)]: 1.5 years (0.05–14.8)
and 11.5 years (1.5–17.7), p<0.001, respectively. Median
durations of mechanical ventilation and stay at the ICU
were longer in the liver than in the kidney patients (Table 1).
Tacrolimus dosing requirements and disposition
Median tacrolimus doses were similar in both transplant
groups, with large interindividual variation in tacrolimus
doses over the first 14 days post-transplant: 0.1 mg/kg
(range 0.01–0.35, IQR 0.08–0.15) for kidney and 0.1 mg/
kg (range 0.01–0.31, IQR 0.08–0.16) for liver recipients
(Table 2). On average 9 tacrolimus concentrations (range 4–
12) per patient were available for the first 14 days post-
transplant. Median concentration/dose ratios (as surrogate
measure of clearance rate) also showed large interindividual
variation: 78 (range 25–280, IQR 45–108) ng/ml*mg/kg/
12h for kidney and 87 ng/ml*mg/kg/12h (range 25–280,
IQR 58–139) for liver recipients.
Less than 40% of all tacrolimus concentrations were in
the predefined therapeutic target range (10–15 ng/ml), as
shown in Fig. 1. In the kidney recipients, more than 50% of
all concentrations were below the therapeutic target range.
In the liver recipients, 33% of concentrations were below
and 25% of all concentrations above this range. In this
group, very high concentrations were observed.
Effect of CYP3A5 and ABCB1 genotype on tacrolimus
dosing and concentrations
DNA for both CYP3A5 and ABCB1 genotyping was
available for 39 kidney and 32 liver recipients. Missing
results were due to limitations in sample collection logistics
and DNA analysis. The genotyped and nongenotyped
groups did not differ in age, gender, weight, or tacrolimus
exposure. DNA for CYP3A5 genotyping was available for
1234 Eur J Clin Pharmacol (2011) 67:1231–124144 of 48 kidney recipients and for 35 of 42 liver recipients.
Genotype distribution for kidney recipients was n=1, 15,
and 28, respectively, for CYP3A5*1/*1, *1/*3, and *3/*3.
Similarly, distribution in liver recipients was n=1, 12, and
22. Genotype distribution was in Hardy-Weinberg equilib-
rium for both groups (p=0.53 and p=0.67, respectively).
In kidney recipients, CYP3A5 genotype was significantly
associated with median tacrolimus dosing requirements,
number of dose changes, and concentration/dose ratio
(Table 3). CYP3A5 expressors needed higher tacrolimus
doses [median 0.14 (range 0.07–0.21) vs. 0.09 (0.01–0.35)
mg/kg/12h, p=0.001] than nonexpressors (Fig. 2). CYP3A5
expressors also needed more upward dose changes, had
lower median tacrolimus concentrations, and had lower C/
D ratios (Table 3). In contrast, in liver recipients, we did not
observe a relationship between recipient CYP3A5 and
tacrolimus dosing requirements (Fig. 2), concentrations, or
C/D ratios (Table 3).
DNA for ABCB1 genotyping was available for 45 kidney
and 32 liver recipients. Genotype distribution is shown in
Table 4. Genotype distribution was in Hardy-Weinberg
equilibrium for all three polymorphisms tested in both
transplant groups.
Upon inspection of the individual boxplots of dosing
requirements vs. individual ABCB1 SNPs, in liver, but not
kidney, recipients homozygous for all three T alleles of
polymorphisms, we noticed a trend towards higher dosing
requirements. We then decided to analyze the relationship
of the TT-TT-TT haplotype and found that liver recipients
with this haplotype (n=3) needed higher tacrolimus doses
than the other patients (n=29) [0.26 (0.15–0.32) vs. 0.11
(0.01–0.25); p=0.013].
Effect of age and PRISM on tacrolimus dosing
and concentrations
Children younger than <5 years of age needed higher
tacrolimus doses per kilogram of body weight than older
children after both kidney and liver transplant (Fig. 3) [kidney:
median 0.15 (range: 0.07–0.35) vs. 0.09 (0.02–0.20) mg/kg/
12h, p=0.046, liver: 0.12 (0.04–0.32) vs. 0.09 (0.01–-0.18)
mg/kg/12h, p=0.038].
The PRISM mortality scores were not correlated with
tacrolimus dosing requirements, tacrolimus trough concen-
trations, or concentration/dose ratios in both transplant
groups. Tacrolimus disposition did not differ between
pediatric liver transplant recipients with (n=7) or without
(n=35) initial graft liver failure.
Fig. 1 Distribution of tacrolimus concentrations in relation to
therapeutic target level by transplant type
Table 2 Tacrolimus (tac) dosing characteristics of the 90 subjects by transplant type
Kidney Liver
Number Median Range Number Median Range P-value
Tac samples per patient 48 9 2–11 42 9 5–12 0.221
Median tac trough level (ng/mL) 48 9 2.8–15.5 42 11.5 5–15 0.000
Median tac dose (mg/kg) 48 0.1 0.02–0.35 42 0.1 0.01–0.32 0.389
Conc/dose (ng/ml per mg/kg) 48 78 25–280 42 87 25–1,939 0.162
Tac concentrations <5 ng/mL 48 5 0–11 42 3 0–9 0.003
Tac concentrations 10–15 ng/mL 48 2 0–94 2 30 –7 0.033
Tac concentrations >15 ng/mL 48 0 0–34 2 20 –5 0.000
Upward dose changes 48 4 0–84 2 41 –8 0.889
Downward dose changes 48 2 0–54 2 30 –5 0.010
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In kidney recipients, in multivariate analysis, both younger
age and CYP3A5 expressor genotype were independently
associated with higher tacrolimus dosing requirements
(r
2=0.362, corrected model p=0.0001, age F-value 4.6,
p=0.001, CYP3A5 genotype F-value 1.3, p=0.005).
Children older than 5 years of age who were CYP3A5
nonexpressors needed 0.09 (0.02–0.15) mg/kg/12h,
whereas children younger than 5 years who were
CYP3A5 expressors needed 0.19 (0.18–0.2) mg/kg/12h
tacrolimus. Patients younger than 5 who were nonex-
pressors as well as patients older than 5 who were
expressors needed on average 0.13 mg/kg/12h (range
0.07–0.35 mg/kg/12h).
Discussion
We aimed to study the interplay of age, genotype, and
disease severity on tacrolimus disposition in the direct post-
transplant period in 48 pediatric kidney and 42 pediatric
liver transplant recipients. In a large proportion of our
patients, tacrolimus concentrations were outside the thera-
peutic window in the first 14 days after transplant. Our
results show that in pediatric kidney recipients, the patient’s
age and CYP3A5 genotype correlate with median tacroli-
mus dosing requirements and concentration/dose ratio in
the first 14 days after transplant. In contrast, in pediatric
liver recipients, age at transplant and ABCB1 genotype
seem to correlate with tacrolimus dosing requirements. We
did not find a relation between disease severity, as
determined by the PRISM score, and dosing requirements
for either transplant group. Interestingly, in the kidney
recipients, both younger age and CYP3A5 expressor
genotype were independently associated with higher dosing
requirements. This observation is important as it empha-
sizes the combined effect of genetic variation and ontogeny
in relation to drug disposition. It has been shown in very
young children that immaturity of drug metabolizing
Fig. 2 Relationship between recipient CYP3A5 genotype and
tacrolimus dosing requirements. Median (horizontal line), 5th and
95th percentiles (box), and range of tacrolimus dosing requirements by
CYP3A5 expressor genotype of the subjects. The denominators for
each group are indicated. Of the kidney recipients, CP3A5 expressors
needed more tacrolimus than nonexpressors (p<0.05)
Table 3 Comparison of tacrolimus (tac) dosing characteristics by CYP3A5 genotype
Kidney recipients Liver recipients
CYP3A5 expressor
(n=16)
CYP3A5 nonexpressor
(n=28)
CYP3A5 expressor
(n=13)
CYP3A5 nonexpressor
(n=22)
Median (range) P Median (range) P
Median tac trough level (ng/mL) 7.3 (4.7–11.1) 10.3 (2.8–15.5) 0.01 10.8 (8.1–14.8) 11.0 (5.0–15.4) 0.80
Median tac dose (mg/kg) 0.14 (0.07–0.20) 0.09 (0.02–0.35) 0.00 0.14 (0.06–0.32) 0.1 (0–0.26) 0.22
Conc/dose (ng/mL per mg/kg) 50.1 (25.5–92.5) 103.1 (31.3–280.3) 0.00 75.8 (38–136) 105 (24.7–1,939) 0.24
Tac concentrations <10 ng/mL (n)7 ( 2 –11) 4 (0–7) 0.00 3 (1–9) 3 (0–7) 0.49
Tac concentrations 10–15 ng/mL (n)2 ( 0 –5) 3 (0–9) 0.11 3 (1–7) 3 (0–7) 0.99
Tac concentrations >15 ng/mL (n)0 ( 0 –2) 0 (0–3) 0.05 1 (0–5) 2 (0–5) 0.43
Upward dose changes (n)4 ( 3 –8) 3 (0–7) 0.00 4 (1–8) 4 (1–6) 0.60
Downward dose changes (n)1 ( 0 –4) 1 (0–4) 0.56 3 (0–5) 3 (0–5) 0.85
*P<0.05 CYP3A5 expressors vs. nonexpressors
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disposition [22, 23]. In our study, patients were well above
the neonatal age, therefore such an effect of ontogeny on
gene-related variation in drug metabolism is less likely. Our
results suggest that tacrolimus starting dosing guidelines in
children should reflect both age and CYP3A5 genotype to
reduce the time needed to reach therapeutic concentrations
directly after transplant.
Effect of genotype
We were surprised to find a CYP3A5 genotype effect so
early after transplant, as other covariates such as post-
surgical inflammation, renal impairment, and changes in
albumin and hematocrit concentrations could have obscured
pharmacogenetic variation in tacrolimus exposure and
dosing. In another study in pediatric kidney patients with
Table 4 Relationship of ABCB1 genotype and tacrolimus (tac) dosing and disposition
Transplant type
Kidney Liver
Median Minimum Maximum Number Median Minimum Maximum Number
ABCB1C3435T
Median tac dose (mg/kg) CC 0.12 0.07 0.19 7 0.09 0.04 0.22 10
CT 0.09 0.02 0.20 16 0.11 0.00 0.25 15
TT 0.11 0.07 0.35 16 0.15 0.09 0.32 7
Conc/dose (ng/ml per mg/kg) CC 61.26 38.68 90.72 7 85.46 24.73 364.00 10
CT 101.16 25.48 280.31 16 96.95 33.20 1,939.80 15
TT 50.07 31.34 156.40 16 72.14 41.13 209.89 7
Median tac trough level (ng/mL) CC 9.10 4.70 11.05 7 11.18 5.00 14.40 10
CT 9.38 4.45 15.50 16 12.05 8.10 15.45 15
TT 8.43 2.80 13.05 16 10.40 8.10 15.10 7
ABCB1C1236T
Median tac dose (mg/kg) CC 0.11 0.02 0.19 11 0.11 0.07 0.22 11
CT 0.09 0.04 0.20 16 0.10 0.00 0.25 15
TT 0.11 0.07 0.35 12 0.15 0.06 0.32 6
Conc/dose (ng/ml per mg/kg) CC 0.10 38.68 280.31 11 0.11 24.73 190.95 11
CT 65.83 25.48 267.59 16 81.82 33.20 1,939.80 15
TT 87.04 31.34 156.40 12 121.22 41.13 281.75 6
Median tac trough level (ng/mL) CC 72.63 4.45 10.60 11 65.17 5.00 15.45 11
CT 77.40 2.80 15.50 16 87.25 8.25 15.10 15
TT 8.25 3.15 13.05 12 10.65 8.10 14.80 6
ABCB1G2677AT
Median tac dose (mg/kg) GG 0.11 0.02 0.17 10 0.11 0.06 0.22 12
GT 0.09 0.04 0.20 17 0.10 0.00 0.25 13
AT 0.15 0.15 0.15 1 0.08 0.08 0.08 1
GA 0.19 0.18 0.19 2
TT 0.09 0.07 0.35 9 0.15 0.12 0.32 6
Conc/dose (ng/ml per mg/kg) GG 71.61 38.92 280.31 10 83.06 24.73 281.75 12
GT 90.72 25.48 267.59 17 136.14 33.20 1,939.80 13
AT 67.77 67.77 67.77 1 133.77 133.77 133.77 1
GA 49.97 38.68 61.26 2
TT 94.77 31.34 156.40 9 65.17 41.13 121.22 6
Median tac trough level (ng/mL) GG 8.48 4.45 10.60 10 10.33 5.00 13.60 12
GT 9.40 2.80 15.50 17 12.40 8.70 15.45 13
AT 10.80 10.80 10.80 1 8.25 8.25 8.25 1
GA 9.00 6.95 11.05 2
TT 8.90 3.15 13.05 9 10.60 8.10 14.80 6
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transplant. A single tacrolimus AUC was determined
20 ±12 days after transplant. In contrast, tacrolimus dosing
requirements were not different according to CYP3A5
genotype in the first 3 months after transplant in adolescent
kidney transplant patients (n=27), but this lack of associ-
ation may be due to a lack of power due to the small sample
size studied [10].
In pediatric liver recipients, we could not identify a
relationship between recipient CYP3A5 genotype and tacro-
limus dosing. The main reason for this lack of association is
probably that variations in tacrolimus exposure are largely
dependent on variation in hepatic metabolism and to a lesser
extent on intestinal metabolism. Hence, donor CYP3A5
genotype may be more important to explain variability in
tacrolimus dosing requirements than the recipient’s genotype.
Unfortunately, we were not able to collect donor DNA to test
this assumption. Our hypothesis is confirmed by data from
Fukudo et al., who estimated tacrolimus pharmacokinetics,
using trough concentrations, in a cohort of 65 Japanese
pediatric living-related liver recipients up to 50 days post-
transplant [25]. Donor CYP3A5 genotype and recipient
intestinal ABCB1 expression but not recipient CYP3A5
genotype were associated with (recovery of) tacrolimus oral
clearance immediately after transplant.
In liver recipients, we found higher dosing requirements
in children with the TT-TT-TT haplotype. Our results are in
contrast with other studies in adults and children [26]. Most
studies did not find a relationship between tacrolimus
dosing requirements or disposition and ABCB1 genotype in
liver transplant patients. In one study in 51 pediatric liver
recipients, carriers of different variant alleles (e.g., G2677T/
A, C3425T, T-T-T haplotype) had higher C:D ratios
(possibly reflecting lower clearance) <3 years after trans-
plant [13]. This result seems to contrast our results. We
found a trend (not significant) towards lower C:D ratios in
patients with the TT-TT-TT haplotype. A possible explana-
tion for these contradicting results is that, early after liver
transplant, intestinal ABCB1 genotype in concert with
intestinal CYP3A4 largely determines variation in tacroli-
mus disposition. Lower intestinal ABCB1 expression may
result in more tacrolimus available for intestinal CYP3A4
metabolism, leading to lower systemic tacrolimus concen-
trations. Later after liver transplant, when the liver is fully
regenerated, hepatic CYP3A5 may be more important. This
is also supported by the lack of a relationship between
ABCB1 genotype and tacrolimus dosing requirements in
our kidney recipients. This hypothesis stems from observa-
tions of a gender effect on the interaction between ABCB1
2677 genotype and CYP3A4 expression. [27, 28]. There is
a significant interaction between this variant (2677 SNP)
and a 6 bp deletion variant of NR1I2 (PXR) influencing
CYP3A4 expression [28]. To our knowledge, none of the
other adult or pediatric studies specifically studied a gender
effect of ABCB1 genotype. Our sample size was too small
to study the effect of gender in relation to the ABCB1
genotype and tacrolimus disposition. In addition, a gender
effect on CYP3A4 expression is likely absent in prepubertal
children. Another explanation for our finding of an ABCB1
effect in liver recipients may be a type I error due to the
small size of our patient population. Only 3 (TT-TT-TT
haplotypes) patients had the variant genotype in a total
genotyped population of 32 patients. For this reason, we
refrained from studying the interaction between ABCB1
genotype and age in the liver patients.
The lack of a relationship between ABCB1 polymor-
phisms and tacrolimus dosing and disposition in our
pediatric kidney recipients is consistent with studies from
adult and pediatric kidney recipients [24, 29, 30]. In
contrast, others did find a relationship between ABCB1
genotype and tacrolimus disposition in adult kidney
recipients [31–33].
Effect of age
In both kidney and liver patients, children younger than 5
years of age needed more tacrolimus than older children.
Our findings are in line with previous studies in pediatric
Fig. 3 Relationship between age and tacrolimus dosing requirements.
Median (horizontal line), 5th and 95th percentiles (box), and range of
tacrolimus dosing requirements by age of the subjects. Children less
than 5 years of age needed more tacrolimus than older children in both
transplant groups (p<0.05)
1238 Eur J Clin Pharmacol (2011) 67:1231–1241liver and kidney recipients [3, 34, 35, 36, 37]. The reason
why younger children need more tacrolimus than older
children to reach the same tacrolimus target concentration is
unknown. A wide range of age-related differences in drug
disposition such as CYP3A4/5 metabolism and p-gp
transport, volume of distribution, protein and erythrocyte
binding, or renal function has been suggested [3]. To our
knowledge, definite data are lacking on the impact of these
possible mechanisms on tacrolimus disposition in children.
Variation in concentrations
In our patient population rigorous therapeutic drug moni-
toring was practiced, which is apparent from a median
(range) of 9 (2–12) tacrolimus concentrations and 6 (1–11)
dose changes in the first 14 days post-transplant. Despite
this rigorous approach, less than 40% of all tacrolimus
concentrations were within the predefined target range (10–
15 ng/ml). Also, 33% of kidney and 76% of liver recipients
had at least one supratherapeutic tacrolimus concentration.
For the kidney recipients, this percentage is lower than
reported in a UK pediatric renal transplant cohort (65 vs.
33% in our patients) [38]. This difference may be explained
by lower initial tacrolimus doses in our patients than in UK
patients (0.1 vs. 0.15 mg/kg twice daily). In pediatric liver
transplant patients, only 27% of all concentrations were in
the therapeutic range, in a study comparing buccal versus
nasogastric administered tacrolimus [39]. As has been
illustrated in adults, even in the context of a clinical trial,
achieving target drug concentrations is challenging, espe-
cially early after transplant [40]. It is to be expected that
incorporation of known covariates, such as CYP3A5
genotype and age, in tacrolimus dosing regimens may
reduce suboptimal tacrolimus dosing, as we found a
relationship between genotype and nontherapeutic tacroli-
mus concentrations.
We hypothesized that part of the variation in tacroli-
mus disposition early after transplant may be due to
variation in disease severity. We used a compound
disease score (PRISM) to evaluate the role of disease
severity on tacrolimus disposition but could not identify
an effect. One limitation of the PRISM score is that it
only takes into account the worst clinical and lab results
within the first 24 h after ICU admission. Hence,
variation in disease state after the first 24 h is not taken
into account. In addition, as this is a compounded score,
variations only in liver or kidney graft function that may
impact tacrolimus metabolism may be missed using this
score. We did, however, not find a difference in
tacrolimus disposition when we compared patients with
and without initial graft failure. In adult liver recipients,
a more sensitive test of liver function, the LiMAx test,
could predict tacrolimus trough levels [41].
Limitations
A limitation of our study is that tacrolimus dosing
information was collected retrospectively from hospital
databases. This may contribute to unexplained variation in
dosing requirements, for example, when a child vomits and
the drug needs to be re-administered. Also, it was not
reported clearly how the drug was administered, by mouth,
gastric, or duodenal tube, nor was it clear if the drug was
given as suspension or as tablets. Furthermore, it was not
known if the patient was receiving oral feeds or parenteral
nutrition, which may also have contributed to unexplained
variation in oral absorption. Previous studies have shown
that different administration modes and fasting may also
contribute to variation in oral tacrolimus pharmacokinetics
[2, 42]. Further studies need to show if tacrolimus oral
granules formulation could improve early GI absorption of
the drug in children with consequently more stable
exposure. Another limitation is that we did not include
deceased patients, as it was not possible to collect DNA.
Deceased patients may have suffered more frequently from
transplant rejection and serious adverse events, resulting in
death. It would have been interesting to include these
patients, to determine if they were frequent outliers with
respect to dosing requirements in relation to their CYP3A5
genotype. In addition, the lack of impact of PRISM score
on tacrolimus disposition in this cohort may have been due
to this lack of inclusion of deceased patients, as this might
have contributed to a larger variation in PRISM scores.
Based on our results, tacrolimus dosing in pediatric kidney
transplant patients could be based on genotype and age.
Starting doses of tacrolimus as high as 0.2 mg/kg/12h could
be considered inyoung (<5 years of age) CYP3A5 expressors
(double the frequently used start dose). For the other age-
genotype combinations, the effect was less pronounced (0.13
mg/kg/12h for older, CYP3A5 expressors and younger,
nonexpressors vs. 0.9 mg/kg/12h for older, nonexpressors).
In adults, a recent genotype-based dosing trial showed
indeed that genotype-based dosing resulted in a shorter
time to reach therapeutic levels (8 vs. 25 days in 75% of
patients). However, no difference in rejection rate was
found [43]. Additionally, adult CYP3A5*3 expressors
seem at higher risk to develop tacrolimus-induced neph-
rotoxicity, despite similar or lower tacrolimus exposure
[44]. Hence, at this time genotype-based dosing in
children might need to be restricted to trials evaluating
its short- and long-term effect.
Conclusion
In conclusion, our results indicate that recipient CYP3A5
genotype and age independently contribute to the variation
Eur J Clin Pharmacol (2011) 67:1231–1241 1239in tacrolimus dosing requirements and successful achieve-
ment of therapeutic tacrolimus concentrations in pediatric
kidney recipients. In this population, individualized dosing
schedules, incorporating both age and recipient CYP3A5
genotype may be needed to optimize tacrolimus dosing. In
pediatric liver recipients, our results suggest that recipient
ABCB1 genotype and age, but not CYP3A5 genotype
contribute to tacrolimus dosing requirements. Further
studies should focus on the design and validation of
genotype (recipient and donor) and age-based dosing
regimens of tacrolimus, as well as on the effect of
individualized dosing on outcome, i.e., transplant rejection
rates and adverse events, such as nephrotoxicity.
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